公开(公告)号：WO2009015908A2

公开(公告)日：2009-02-05

申请号：PCT/EP2008006451

申请日：2008-07-25

Applicant: BAYER SCHERING PHARMA AG ,  MORPHOSYS AG ,  PETRUL HEIKE ,  MENRAD ANDREASE ,  WILLUDA JOERG ,  ZOPF DIETER ,  GLIENKE JENS ,  PRASSLER JOSEF ,  POPP ANDREAS ,  STEIDL STEFAN ,  PRACHT CATRIN

Inventor： PETRUL HEIKE ,  MENRAD ANDREASE ,  WILLUDA JOERG ,  ZOPF DIETER ,  GLIENKE JENS ,  PRASSLER JOSEF ,  POPP ANDREAS ,  STEIDL STEFAN ,  PRACHT CATRIN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

CPC classification number: C07K16/2866 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

Abstract: The invention concerns antibodies and antibody fragments, specifically recognising the EphB4 receptor comprising heavy chains and light chain, comprising light and heavy CDR's, and their use as medicament for the treatment of pathological angiogenesis, in particular cancer therapy.

Abstract translation: 本发明涉及特异性识别包含重链和轻链的EphB4受体的抗体和抗体片段，其包含轻链和重链CDR，以及它们作为用于治疗病理性血管生成，特别是癌症治疗的药物的用途。

公开(公告)号：WO2010017086A1

公开(公告)日：2010-02-11

申请号：PCT/US2009/052192

申请日：2009-07-30

Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH ,  LITZENBURGER, Tobias ,  MILLER, Sandra ,  PRACHT, Catrin ,  BOXHAMMER, Rainer ,  MAGRAM, Jeanne ,  GIBLIN, Patricia ,  RAJOTTE, Daniel

Inventor： LITZENBURGER, Tobias ,  GIBLIN, Patricia ,  RAJOTTE, Daniel

IPC: A61K39/395 ,  A61P37/00 ,  C07K16/28

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.

Abstract translation: 本发明涉及PAR-2受体扩增炎症反应的认识，因此PAR-2活化的作用者可用于调节炎症反应，从而赋予患者治疗益处。 本发明特别涉及使用PAR-2效应物治疗由炎症，癌症和损伤引起的炎症和伤害感受（疼痛）。 本发明特别涉及PAR-2活化的负效应物，更特别地涉及作为PAR-2活化的负效应物的抗PAR-2抗体。

公开(公告)号：WO2009015908A3

公开(公告)日：2009-02-05

申请号：PCT/EP2008/006451

申请日：2008-07-25

Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT ,  MORPHOSYS AG ,  PETRUL, Heike ,  MENRAD, Andrease ,  WILLUDA, Jörg ,  ZOPF, Dieter ,  GLIENKE, Jens ,  PRASSLER, Josef ,  POPP, Andreas ,  STEIDL, Stefan ,  PRACHT, Catrin

Inventor： PETRUL, Heike ,  MENRAD, Andrease ,  WILLUDA, Jörg ,  ZOPF, Dieter ,  GLIENKE, Jens ,  PRASSLER, Josef ,  POPP, Andreas ,  STEIDL, Stefan ,  PRACHT, Catrin

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395

Abstract: The invention concerns antibodies and antibody fragments, specifically recognising the EphB4 receptor comprising heavy chains and light chain, comprising light and heavy CDR's, and their use as medicament for the treatment of pathological angiogenesis, in particular cancer therapy.

公开(公告)号：EP2313110A1

公开(公告)日：2011-04-27

申请号：EP09790973.3

申请日：2009-07-30

Applicant: Boehringer Ingelheim International GmbH ,  Miller, Sandra ,  Pracht, Catrin ,  Boxhammer, Rainer ,  Magram, Jeanne

Inventor： LITZENBURGER, Tobias ,  GIBLIN, Patricia ,  RAJOTTE, Daniel ,  MILLER, Sandra ,  PRACHT, Catrin ,  BOXHAMMER, rainer ,  MAGRAM, Jeanne

IPC: A61K39/395 ,  A61P37/00 ,  C07K16/28

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.